Skip to main content
SpringerLink
Log in

Tumor Necrosis Factor Inhibition

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

  • 1491 Accesses

Abstract

TNF antagonists revolutionized the treatment of several high-needs inflammatory conditions including plaque psoriasis and hidradenitis suppurativa. After an initial, sputtering start in MS, septic shock, and congestive heart failure, clinical trials in rheumatoid arthritis established a development path in chronic inflammatory diseases. Plaque psoriasis was a serendipitous passenger on the psoriatic arthritis train. Over many years of development, dozens of clinical trials, and thousands of patients in registries, we know TNF to be a central cytokine mediating many chronic inflammatory diseases. We also know that therapeutic blockade of TNF is remarkably safe. Yet to be established are collateral benefits of treatment with TNF antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–56.

    Article  CAS  PubMed  Google Scholar 

  2. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007;179:4307–12.

    Article  CAS  PubMed  Google Scholar 

  3. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.

    Article  CAS  PubMed  Google Scholar 

  4. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–33.

    Article  CAS  PubMed  Google Scholar 

  5. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry. 2002;41:9462–9.

    Article  CAS  PubMed  Google Scholar 

  6. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol. 2005;23:787–819.

    Article  CAS  PubMed  Google Scholar 

  7. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.

    Article  CAS  PubMed  Google Scholar 

  8. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27:19–26.

    Article  CAS  PubMed  Google Scholar 

  10. Mikkola ML. TNF superfamily in skin appendage development. Cytokine Growth Factor Rev. 2008;19:219–30.

    Article  CAS  PubMed  Google Scholar 

  11. Sedy J, Bekiaris V, Ware CF. Tumor necrosis factor superfamily in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2015;7:a016279.

    Article  PubMed Central  CAS  Google Scholar 

  12. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986–9.

    CAS  PubMed  Google Scholar 

  14. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988;6:1328–34.

    Article  CAS  PubMed  Google Scholar 

  15. Fukushima T, Yamamoto M, Ikeda K, Tsugu H, Kimura H, Soma G, Tomonaga M. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res. 1998;18:3965–70.

    CAS  PubMed  Google Scholar 

  16. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Al ET. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:223–9.

    Article  CAS  PubMed  Google Scholar 

  17. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662–4.

    Article  CAS  PubMed  Google Scholar 

  18. Abraham E. Therapies for sepsis. Emerging therapies for sepsis and septic shock. West J Med. 1997;166:195–200.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, van der Auwera P, Lenercept Study G. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med. 2001;29:503–10.

    Article  CAS  PubMed  Google Scholar 

  20. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Al ET. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study Group. JAMA. 1995;273:934–41.

    Article  CAS  PubMed  Google Scholar 

  21. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001;29:S121–5.

    Article  CAS  PubMed  Google Scholar 

  22. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999: 53:457–65.

    Google Scholar 

  23. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–40.

    Article  CAS  PubMed  Google Scholar 

  24. Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: Renewal (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002;4:559–61.

    Article  CAS  PubMed  Google Scholar 

  25. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–6.

    Article  CAS  PubMed  Google Scholar 

  26. Mann DL, Mcmurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109:1594–602.

    Article  CAS  PubMed  Google Scholar 

  27. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163–8.

    Article  CAS  PubMed  Google Scholar 

  28. Dayer JM, Breard J, Chess L, Krane SM. Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest. 1979;64:1386–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Al ET. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–90.

    Article  CAS  PubMed  Google Scholar 

  30. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.

    Article  CAS  PubMed  Google Scholar 

  31. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, Mcdonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–86.

    Article  CAS  PubMed  Google Scholar 

  32. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90.

    Article  CAS  PubMed  Google Scholar 

  33. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as Monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.

    Article  CAS  PubMed  Google Scholar 

  34. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study, G. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.

    Article  CAS  PubMed  Google Scholar 

  35. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.

    Article  CAS  PubMed  Google Scholar 

  36. Berthold-Losleben M, Himmerich H. The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. Curr Neuropharmacol. 2008;6:193–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Schmidt FM, Kirkby KC, Himmerich H. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression—report of two cases. Psychiatr Danub. 2014;26:288–90.

    PubMed  Google Scholar 

  39. Papp K. Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. Curr Med Res Opin. 2010;26:2287–300.

    Article  CAS  PubMed  Google Scholar 

  40. Stevens SR, Chang TH. History of development of TNF inhibitors. In: Weinberg JM, Buchholz R, editors. TNF-alpha inhibitors. Birkhäuser Basel: Basel; 2006.

    Google Scholar 

  41. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12:147–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Highlights of prescribing information 125057s397lbl. In: ADMINISTRATION, F. A. D. (ed.). U.S Department of Health and Human Services. 2016.

    Google Scholar 

  43. van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177–85.

    PubMed  Google Scholar 

  44. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165:661–8.

    Article  CAS  PubMed  Google Scholar 

  45. Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165:652–60.

    Article  CAS  PubMed  Google Scholar 

  46. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–38.

    Article  PubMed  CAS  Google Scholar 

  47. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–51.

    Article  CAS  PubMed  Google Scholar 

  48. Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552–61.

    Article  CAS  PubMed  Google Scholar 

  49. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74.

    Article  CAS  PubMed  Google Scholar 

  50. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(31):e1–15.

    Google Scholar 

  51. Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, Wang BX, Zhang FR, Li CY, Liu XM, Tu CX, Ji SZ, Shen Y, Zhu XJ. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J. 2012;125:1845–51.

    CAS  PubMed  Google Scholar 

  52. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.

    Article  PubMed  Google Scholar 

  53. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–66.

    Article  CAS  PubMed  Google Scholar 

  54. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.

    Article  PubMed  Google Scholar 

  55. Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37:299–310.

    Article  CAS  PubMed  Google Scholar 

  56. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen Y-K, Szapary P, Randazzo B, Reich K. A phase 2 trial of Guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136–44.

    Article  CAS  PubMed  Google Scholar 

  57. Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167:180–90.

    Article  CAS  PubMed  Google Scholar 

  58. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.

    Article  CAS  PubMed  Google Scholar 

  59. 125057s110_MedR_P1: Medical Reviews sBLA125057/110: Humira—adalimumab for adults who are candidates for systemic therapy or phototherapy. In: RESEARCH, C. F. D. E. A. (ed.). U.S. Food and Drug Administration. 2008.

    Google Scholar 

  60. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2013;27:634–42.

    Article  CAS  PubMed  Google Scholar 

  62. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–32.

    PubMed  PubMed Central  Google Scholar 

  63. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3–11.

    Article  PubMed  Google Scholar 

  64. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–35.

    Article  PubMed  Google Scholar 

  65. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72.

    Article  CAS  PubMed  Google Scholar 

  66. Kavanaugh A, Mcinnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.

    Article  CAS  PubMed  Google Scholar 

  67. Kavanaugh A, Mcinnes IB, Mease PJ, Krueger GG, Gladman DD, Van Der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013;72:1777–85.

    Article  CAS  PubMed  Google Scholar 

  68. Kavanaugh A, Mcinnes IB, Mease P, Krueger GG, Gladman D, Van Der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Antoni C, Krueger G, De Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley L, Kavanaugh A, IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005b;64:1150–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005a;52:1227–36.

    Article  CAS  PubMed  Google Scholar 

  71. Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, RESPOND investigators. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541–8.

    Article  CAS  PubMed  Google Scholar 

  72. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study, G. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.

    Article  CAS  PubMed  Google Scholar 

  73. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–88.

    Article  CAS  PubMed  Google Scholar 

  74. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van Den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68:702–9.

    Article  CAS  PubMed  Google Scholar 

  75. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH, M02-570 Study Group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040–50.

    CAS  PubMed  Google Scholar 

  76. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, Van Der Heijde D. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.

    Article  CAS  PubMed  Google Scholar 

  77. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53:358–9.

    Article  PubMed  Google Scholar 

  78. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52:522–6.

    Article  PubMed  Google Scholar 

  79. Sand FL, Thomsen SF. TNF-alpha inhibitors for chronic Urticaria: experience in 20 patients. J Allergy (Cairo). 2013;2013:130905.

    Google Scholar 

  80. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:e55–79.

    Article  PubMed  Google Scholar 

  81. Sanchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Rios-Fernandez R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Behcet's disease, sarcoidosis, and noninfectious uveitis. Mediat Inflamm. 2013;2013:286857.

    Google Scholar 

  82. Wolverton SE. Comprehensive dermatologic drug therapy. Edinburgh: Saunders/Elsevier; 2013.

    Google Scholar 

  83. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.

    CAS  PubMed  Google Scholar 

  84. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17.

    Article  CAS  PubMed  Google Scholar 

  85. Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–42.

    Article  CAS  PubMed  Google Scholar 

  86. Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, Van Der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012a;157:846–55.

    Article  PubMed  Google Scholar 

  87. Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Two phase 3 trials of adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422–34.

    Article  CAS  PubMed  Google Scholar 

  88. Hessam S, Sand M, Gambichler T, Bechara FG. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015;73:998–1005.

    Article  CAS  PubMed  Google Scholar 

  89. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–5.

    Article  PubMed  Google Scholar 

  90. Thomsen SF, Sand FL. Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa. J Dermatolog Treat. 2015;26:97–8.

    Article  PubMed  Google Scholar 

  91. Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, Gu Y, Okun MM, Kerdel F. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol. 2014;171:1561–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, Abildstrom SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–57.

    Article  CAS  PubMed  Google Scholar 

  93. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41.

    Article  CAS  PubMed  Google Scholar 

  94. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009;160:1048–56.

    Article  CAS  PubMed  Google Scholar 

  95. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165:1066–73.

    Article  CAS  PubMed  Google Scholar 

  96. Abuabara K, Lee H, Kimball AB. Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors. Br J Dermatol. 2012;166:233.

    Article  CAS  PubMed  Google Scholar 

  97. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50.

    Article  CAS  PubMed  Google Scholar 

  98. Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, Lasthein S, Lindhardsen J, Kristensen SL, Torp-Pedersen C, Hansen PR. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29:1128–34.

    Article  CAS  PubMed  Google Scholar 

  99. Bolland MJ, Avenell A, Baron JA, Grey A, Maclennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol. 2006;26:406–10.

    Article  CAS  PubMed  Google Scholar 

  101. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, Mcqueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S, INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–75.

    Article  PubMed  Google Scholar 

  102. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai PJR, Razak F, Sharma AM, Anand SS, INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–9.

    Article  PubMed  Google Scholar 

  103. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, Mcqueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.

    Article  PubMed  Google Scholar 

  104. Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, Hsu MC, Yeilding N, Rader DJ, Mehta NN. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012b;67:76–85.

    Article  PubMed  Google Scholar 

  105. Kleinbaum DG, Kupper LL, Nizam A, Rosenberg ES. Applied regression analysis and other multivariable methods. Boston, MA: Cengage Learning; 2013.

    Google Scholar 

  106. Davies HT, Crombie IK. Bias in case-control studies. Hosp Med. 2000a;61:279–81.

    Article  CAS  PubMed  Google Scholar 

  107. Davies HT, Crombie IK. Bias in cohort studies. Hosp Med. 2000b;61:133–5.

    Article  CAS  PubMed  Google Scholar 

  108. Utley M, Gallivan S, Young A, Cox N, Davies P, Dixey J, Emery P, Gough A, James D, Prouse P, Williams P, Winfield J, Devlin JA. Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies. Rheumatology (Oxford). 2000;39:1–2.

    Article  CAS  Google Scholar 

  109. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(199–207):e15.

    Google Scholar 

  110. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011;162:597–605.

    Article  CAS  PubMed  Google Scholar 

  111. Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:414–7.

    Article  PubMed  Google Scholar 

  112. Burmester GR, Panaccione R, Gordon KB, Mcilraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72:517–24.

    Article  CAS  PubMed  Google Scholar 

  113. Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag. 2007;3:245–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15:280–94.

    Article  CAS  PubMed  Google Scholar 

  115. Mercer LK, Galloway JB, Lunt M, Davies R, Low AA, Dixon WG, Watson KD, Symmons DP, Hyrich KL. Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by nocturne et al. Ann Rheum Dis. 2017;76:e4.

    Article  PubMed  Google Scholar 

  116. Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD, Consortium BCC, Symmons DP, Hyrich KL. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2016;76(3):497–503.

    Article  PubMed  Google Scholar 

  117. Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish multiple sclerosis registry. Ann Rheum Dis. 2016;75:785–6.

    Article  CAS  PubMed  Google Scholar 

  118. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Scholvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185–206.

    Article  CAS  PubMed  Google Scholar 

  119. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159–67.

    Article  CAS  PubMed  Google Scholar 

  120. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies, G. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc. 2007;12:16–21.

    Article  CAS  PubMed  Google Scholar 

  122. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11.

    Article  CAS  PubMed  Google Scholar 

  123. Wallis RS. Mathematical models of tuberculosis reactivation and relapse. Front Microbiol. 2016;7:669.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(Suppl 3):S194–8.

    Article  CAS  PubMed  Google Scholar 

  125. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–5.

    Article  CAS  PubMed  Google Scholar 

  126. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Winthrop KL, Furst DE. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy. Ann Rheum Dis. 2010;69:1735–7.

    Article  CAS  PubMed  Google Scholar 

  128. Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26:1127–32.

    Article  CAS  PubMed  Google Scholar 

  130. Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, Feldhamer I, Moser H, Hammerman A, Cohen Y, Cohen AD. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151:533–8.

    Article  PubMed  Google Scholar 

  131. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–74.

    Article  CAS  PubMed  Google Scholar 

  132. Poulin Y, Therien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010;14:100–4.

    Article  PubMed  Google Scholar 

  133. Landauer K, Unutmaz C, Egli S, Berger V, Lais S, Liebig T, Steiner D, Maier J, Rostalski I, Forcellino F, Herrmann A. Process development of ATROSAB, an anti TNFR1 monoclonal antibody: in three steps from research to GMP. BMC Proc. 2011;5(Suppl 8):P42.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity. PLoS One. 2013;8:e72156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Zettlitz KA, Lorenz V, Landauer K, Munkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann R. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010;2:639–47.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Mccann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, Dean JL, Stoop AA, Williams RO. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014;66:2728–38.

    Article  CAS  PubMed  Google Scholar 

  137. Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, Stoop AA, Brennan FM. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum. 2013;65:2262–73.

    Article  CAS  PubMed  Google Scholar 

  138. Steeland S, Puimege L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem. 2015;290:4022–37.

    Article  CAS  PubMed  Google Scholar 

  139. Ameloot P, Brouckaert P. Production and characterization of receptor-specific TNF muteins. Methods Mol Med. 2004;98:33–46.

    CAS  PubMed  Google Scholar 

  140. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P, Chirino AJ, Chung HH, Doberstein SK, Eivazi A, Filikov AV, Gao SX, Hubert RS, Hwang M, Hyun L, Kashi S, Kim A, Kim E, Kung J, Martinez SP, Muchhal US, Nguyen DH, O'brien C, O'keefe D, Singer K, Vafa O, Vielmetter J, Yoder SC, Dahiyat BI. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301:1895–8.

    Article  CAS  PubMed  Google Scholar 

  141. Kitagaki M, Isoda K, Kamada H, Kobayashi T, Tsunoda S, Tsutsumi Y, Niida T, Kujiraoka T, Ishigami N, Ishihara M, Matsubara O, Ohsuzu F, Kikuchi M. Novel TNF-alpha receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J Atheroscler Thromb. 2012;19:36–46.

    Article  CAS  PubMed  Google Scholar 

  142. Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, Taniai M, Nomura T, Kayamuro H, Nabeshi H, Sugita T, Imai S, Nagano K, Yoshikawa T, Fujita T, Nakagawa S, Yamamoto A, Ohta T, Hayakawa T, Mayumi T, Vandenabeele P, Aggarwal BB, Nakamura T, Yamagata Y, Tsunoda S, Kamada H, Tsutsumi Y. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem. 2008;283:998–1007.

    Article  CAS  PubMed  Google Scholar 

  143. Mcalpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, Laferla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34:163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Mccoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci. 2006;26:9365–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Sama DM, Mohmmad Abdul H, Furman JL, Artiushin IA, Szymkowski DE, Scheff SW, Norris CM. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One. 2012;e38170:7.

    Google Scholar 

  146. Yung RL. Etanercept Immunex. Curr Opin Investig Drugs. 2001;2:216–21.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. K Papp Clinical Research and Probity Medical Research, 135 Union Street East, Waterloo, ON, Canada, N2J 1C4

    K. A. Papp MD, PhD

  2. Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Mathew N. Nicholas BMSc

Authors
  1. K. A. Papp MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathew N. Nicholas BMSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. A. Papp MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Papp, K.A., Nicholas, M.N. (2018). Tumor Necrosis Factor Inhibition. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation